Vazomag® (Capsules, Solution) Instructions for Use
ATC Code
C01EB22 (Meldonium)
Active Substance
Meldonium (Rec.INN registered by WHO)
Clinical-Pharmacological Group
A drug that improves tissue metabolism and energy supply
Pharmacotherapeutic Group
Metabolic agent
Pharmacological Action
A metabolic-improving agent, an analog of gamma-butyrobetaine. It inhibits gamma-butyrobetaine hydroxylase, suppresses the synthesis of carnitine and the transport of long-chain fatty acids across cell membranes, and prevents the accumulation in cells of activated forms of non-oxidized fatty acids – derivatives of acylcarnitine and acylcoenzyme A.
Under ischemic conditions, it restores the balance between oxygen delivery and consumption processes in cells, prevents disruption of ATP transport; simultaneously, it activates glycolysis, which proceeds without additional oxygen consumption. As a result of the decreased carnitine concentration, gamma-butyrobetaine, which has vasodilating properties, is synthesized more intensively. The mechanism of action determines the diversity of its pharmacological effects: increased performance, reduction of symptoms of mental and physical overstrain, activation of tissue and humoral immunity, cardioprotective action.
In case of acute ischemic myocardial damage, it slows down the formation of the necrotic zone and shortens the rehabilitation period. In heart failure, it increases myocardial contractility, increases tolerance to physical load, and reduces the frequency of angina attacks. In acute and chronic ischemic cerebrovascular disorders, it improves blood circulation in the ischemic focus and promotes blood redistribution in favor of the ischemic area. It is effective in vascular and dystrophic pathologies of the ocular fundus. It has a tonic effect on the CNS and eliminates functional disorders of the nervous system in patients with chronic alcoholism during withdrawal syndrome.
Pharmacokinetics
After oral administration, it is rapidly absorbed from the gastrointestinal tract. The bioavailability is about 78%. Cmax in plasma is reached 1-2 hours after administration. It is biotransformed in the body with the formation of two main metabolites, which are excreted by the kidneys. T1/2 is 3-6 hours and depends on the dose.
Indications
For oral or intravenous administration: as part of complex therapy for coronary artery disease (angina pectoris, myocardial infarction), chronic heart failure, dishormonal cardiomyopathy; as part of complex therapy for acute and chronic cerebrovascular disorders (strokes and cerebrovascular insufficiency); reduced performance, physical overstrain (including in athletes), postoperative period to accelerate rehabilitation; withdrawal syndrome in chronic alcoholism (in combination with specific therapy for alcoholism).
For parabulbar administration: acute circulatory disorders in the retina, hemophthalmos and retinal hemorrhages of various etiologies, thrombosis of the central retinal vein and its branches, retinopathies of various etiologies (including diabetic and hypertensive) – for parabulbar administration only.
ICD codes
| ICD-10 code | Indication |
| F10.3 | Withdrawal state |
| H34 | Retinal vascular occlusions |
| H35.0 | Background retinopathy and retinal vascular changes |
| H35.6 | Retinal hemorrhage |
| H36.0 | Diabetic retinopathy |
| H44.8 | Other disorders of globe (including hemophthalmos) |
| I20 | Angina pectoris |
| I21 | Acute myocardial infarction |
| I42 | Cardiomyopathy |
| I50.0 | Congestive heart failure |
| I61 | Intracerebral hemorrhage (cerebrovascular accident of hemorrhagic type) |
| I63 | Cerebral infarction |
| I69 | Sequelae of cerebrovascular diseases |
| Z54.0 | Convalescence following surgery |
| Z73.0 | Burn-out |
| Z73.3 | Stress, not elsewhere classified (physical and mental strain) |
| ICD-11 code | Indication |
| 6C40.4Z | Alcohol withdrawal syndrome, unspecified |
| 8B00.Z | Intracerebral hemorrhage of unspecified site, unspecified |
| 8B11 | Cerebral ischemic stroke |
| 8B25.Z | Sequelae of cerebrovascular disease, unspecified |
| 9B3Z | Disorders of the anterior segment of the eyeball, unspecified |
| 9B71.0Z | Diabetic retinopathy, unspecified |
| 9B74.Z | Retinal vascular occlusion, unspecified |
| 9B78.1Z | Background retinopathy and retinal vascular changes, unspecified |
| 9B78.5 | Retinal hemorrhage |
| 9C0Z | Diseases of the posterior segment of the eye, unspecified |
| 9E1Z | Diseases of the visual system, unspecified |
| BA40.Z | Angina pectoris, unspecified |
| BA41.Z | Acute myocardial infarction, unspecified |
| BC43.Z | Cardiomyopathy, unspecified |
| BD10 | Congestive heart failure |
| QB7Y | Other specified convalescence |
| QD85 | Burn-out |
| QE01 | Stress, not elsewhere classified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Solution
Due to the possibility of developing a stimulating effect, administration in the first half of the day is recommended. The dose is set individually depending on the indications and route of administration.
For oral administration, a single dose is 0.25-1 g, the frequency of administration and duration of treatment depend on the indications.
For intravenous administration, the dose is 0.5-1 g once/day, the duration of treatment depends on the indications.
For parabulbar administration, 0.5 ml of the injection solution with a concentration of 500 mg/5 ml is administered for 10 days.
Capsules
Due to the possibility of developing a stimulating effect, administration in the first half of the day is recommended. The dose is set individually depending on the indications and route of administration.
For oral administration, a single dose is 0.25-1 g, the frequency of administration and duration of treatment depend on the indications.
Adverse Reactions
From the cardiovascular system rarely – tachycardia, changes in blood pressure.
From the central nervous system rarely – psychomotor agitation.
From the digestive system rarely – dyspeptic symptoms.
Allergic reactions rarely – skin itching, redness, rash, edema.
Contraindications
Increased intracranial pressure (including in cases of impaired venous outflow, intracranial tumors), pregnancy, lactation (breastfeeding), children and adolescents under 18 years of age, hypersensitivity to meldonium.
Use in Pregnancy and Lactation
The use of the drug is contraindicated during pregnancy and lactation (breastfeeding).
Use in Hepatic Impairment
Use with caution in liver diseases, especially for a long period of time.
Use in Renal Impairment
Use with caution in kidney diseases, especially for a long period of time.
Pediatric Use
In children and adolescents under 18 years of age, the efficacy and safety of meldonium have not been established.
Meldonium in capsule form is contraindicated for use in children and adolescents under 18 years of age; in syrup form – in children under 12 years of age.
Special Precautions
Use with caution in liver and/or kidney diseases, especially for a long period of time.
Long-term experience in treating acute myocardial infarction and unstable angina in cardiology departments shows that Meldonium is not a first-line agent for acute coronary syndrome.
Drug Interactions
When used concomitantly, Meldonium enhances the action of antianginal agents, some hypotensive drugs, and cardiac glycosides.
With simultaneous use of meldonium with nitroglycerin, nifedipine, alpha-blockers, antihypertensive agents, and peripheral vasodilators, the development of moderate tachycardia and arterial hypotension is possible (caution is required with these combinations).
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Injection solution 500 mg/5 ml: amp. 10 pcs.
Marketing Authorization Holder
Onlinepharm, JSC (Latvia)
Manufactured By
Sopharma, JSC (Bulgaria)
Dosage Form
| Vazomag® | Injection solution 500 mg/5 ml: amp. 10 pcs. |
Dosage Form, Packaging, and Composition
Injection solution colorless, transparent.
| 1 ml | 1 amp. | |
| Meldonium dihydrate | 100 mg | 500 mg |
Excipients : water for injections – up to 1 ml.
5 ml – glass ampoules (10) – contour cell packs (1) – cardboard packs×.
× a sticker ensuring control of the first opening may be applied.
Injection solution 500 mg/5 ml: amp. 10 pcs.
Marketing Authorization Holder
Onlinepharm, JSC (Latvia)
Dosage Form
| Vazomag® | Injection solution 500 mg/5 ml: amp. 10 pcs. |
Dosage Form, Packaging, and Composition
Injection solution colorless, transparent.
| 1 ml | 1 amp. | |
| Meldonium dihydrate | 100 mg | 500 mg |
Excipients : water for injections – up to 1 ml.
5 ml – glass ampoules (10) – contour cell packs (1) – cardboard packs×.
× a sticker ensuring control of the first opening may be applied.
Capsules 250 mg: 20 or 40 pcs.
Marketing Authorization Holder
Onlinepharm, JSC (Latvia)
Dosage Form
| Vazomag® | Capsules 250 mg: 20 or 40 pcs. |
Dosage Form, Packaging, and Composition
Capsules hard gelatin, size No. 1, white/white color; capsule contents – powder white or almost white.
| 1 caps. | |
| Meldonium dihydrate | 250 mg |
Excipients : potato starch – 18.125 mg, colloidal silicon dioxide – 5.5 mg, calcium stearate – 1.375 mg.
Capsule composition titanium dioxide (E171) – 2%, gelatin – up to 100%.
10 pcs. – contour cell packs (2) – cardboard packs×.
10 pcs. – contour cell packs (4) – cardboard packs×.
× a sticker ensuring control of the first opening may be applied.
Belosalic, lotion solution for external use spray 100ml
No-spa pills 40mg, 64pcs
Arbidol, capsules 100mg, 40pcs
Noopept, pills 10mg, 50pcs
Fenotropil pills 100mg, 60pcs
Kagocel pills 12mg, 30pcs
OKI, sachets 80mg 2g, 12pcs
Cerebrolysin, solution for injection 2ml ampoules 10pcs
Mildronate capsules 500mg, 90pcs
Nootropil pills 800mg, 30pcs
Cavinton Comfort, dispersible pills 10mg 90pcs
Picamilon pills 50mg, 60pcs
Phenibut-Vertex pills 250mg, 20pcs
Actovegin pills 200mg, 50pcs
Belosalic, ointment, 30g
Ingavirin capsules 90mg, 10pcs
Cortexin, 10mg, 5ml, 10pcs 